Pipeline
​
Clinical programs for neurological disorders

Advancing Innovative Therapeutics to Restore Neuronal Function

 

​

Loss of neuronal function is a central factor in many nervous system disorders, often leading to increased inflammation, neuron degeneration, and reduced structural plasticity. These deficits can result in cognitive and motor impairments, diminished quality of life, and shortened lifespan.

 

PurMinds has developed a pipeline of proprietary formulations and novel small molecules (NCEs) designed to:

           •     Restore neuronal function

           •     Provide long-lasting therapeutic benefits

           •     Address multiple clinical indications

​

 

PUR100 Series

This proprietary neuroplastogen formulation program will follow the FDA’s botanical drug pathway. The safety and therapeutic potential of the classical neuroplastogens are well-documented through historical human use and contemporary clinical studies. Leveraging this robust evidence, PurMinds sees these therapies as a low-risk, high-promise opportunity. An IND submission is currently underway in partnership with a leading U.S. hospital network, with the first clinical indication targeting anxiety in cancer patients, as well as neurodegenerative diseases.

 

​

PUR500 Series

These engineered molecules are designed from psychedelic scaffolds to stimulate neuron growth and enhance neural architecture without altering consciousness, while also minimizing cardiovascular risks. The PUR500 series is currently in pre-clinical development, with encouraging early results.